Importance of early and deeper responses to long-term survival in CML patients: Implications of BCR-ABL testing in management of CML in Indian setting
The prognosis of patients with chronic myeloid leukemia (CML) has changed radically since the advent of imatinib mesylate, a selective inhibitor of BCR-ABL tyrosine kinase. Shortly thereafter, more potent BCR-ABL inhibitors (dasatinib and nilotinib) were introduced for use in patients resistant to o...
Saved in:
| Main Author: | Mohan B. Agarwal |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2014-01-01
|
| Series: | Indian Journal of Medical and Paediatric Oncology |
| Subjects: | |
| Online Access: | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2014;volume=35;issue=1;spage=10;epage=16;aulast=Agarwal |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Design, Docking Analysis, and Structure–Activity Relationship of Ferrocene-Modified Tyrosine Kinase Inhibitors: Insights into BCR-ABL Interactions
by: Irena Philipova, et al.
Published: (2025-07-01) -
Computational Insights into the Polypharmacological Landscape of BCR-ABL Inhibitors: Emphasis on Imatinib and Nilotinib
by: Rima Hajjo, et al.
Published: (2025-06-01) -
BCR-ABL gene amplification in patients with chronic myeloid leukemia and imatinib resistance
by: S. I. Kutzev, et al.
Published: (2022-11-01) -
Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylate
by: Pratik Deb, et al.
Published: (2014-01-01) -
Characteristics of BCR::ABL1 kinase domain mutations in Vietnamese chronic myeloid leukemia patients
by: Phu Chi Dung, et al.
Published: (2025-01-01)